0
0
VARANASI — The Uttar Pradesh Food and Drugs Department has significantly widened its net in the ongoing investigation into a massive codeine-based cough syrup smuggling syndicate, booking 12 additional pharmaceutical firms in Varanasi on Friday. This latest action brings the total number of implicated entities to nearly 40, exposing a sprawling illicit network that has allegedly funneled millions of bottles of addictive syrup into the black market across multiple states and international borders.
The scandal, which has sent shockwaves through the region’s pharmaceutical sector, centers on the diversion of codeine-phosphate syrup—a prescription medication commonly abused as a recreational narcotic. Officials estimate the syndicate is responsible for the illegal trade of approximately 89 lakh bottles worth over ₹100 crore between 2023 and 2025.
The Investigation Expands
The latest FIRs (First Information Reports) were lodged at the Kotwali police station following a rigorous verification drive by the drug control administration. Inspector Janab Ali of the Food and Drugs Department confirmed that the 12 newly booked firms were identified as “suspicious” during the initial crackdown on November 15, when 26 other companies were charged.
“When our teams went to physically verify these 12 firms, the findings were alarming,” Inspector Ali stated. “The premises were either found locked, or we discovered completely different shops operating at the registered addresses. We issued show-cause notices seeking immediate clarification from the operators, but when they failed to provide any response, we proceeded with legal action.”
This “ghost firm” modus operandi suggests a calculated effort to create a paper trail for illicit drug diversion without any legitimate physical operations.
Anatomy of a Syndicate
Investigators believe the operation was masterminded by Shubham Jaiswal and his father, Bhola Prasad, who allegedly utilized a Ranchi-based firm, Shaily Traders, as a pivot point for the racket. The syndicate reportedly procured vast quantities of codeine-based syrup under the guise of legitimate medical supply.
Instead of reaching patients in need, these supplies were diverted through a complex web of fake invoices and shell companies. The illicit stock was then smuggled out of Uttar Pradesh to neighboring states including Bihar, Jharkhand, and West Bengal. Intelligence reports indicate that a significant portion of the contraband may have been trafficked across the border into Bangladesh, where alcohol prohibition drives a high demand for codeine-based intoxicants.
The Public Health Crisis: “Liquid Opioids”
The crackdown highlights a critical public health issue plaguing India: the rampant abuse of pharmaceutical opioids. Codeine phosphate is a narcotic analgesic and cough suppressant that, when taken in large doses, produces a euphoric high similar to heroin, though less potent.
“Codeine acts on the central nervous system to relieve pain and suppress coughing, but it also depresses respiration,” explains Dr. Rajesh Kumar, a senior addiction psychiatrist not involved in the investigation. “When diverted for recreational use—often mixed with soda or alcohol in a cocktail known as ‘purple drank’ or ‘lean’—the risk of overdose increases dramatically. We are seeing young adults with severe addiction, liver damage from the additives, and in tragic cases, fatal respiratory failure.”
The ease of access to these “liquid opioids” creates a silent epidemic. Unlike street drugs, pharmaceutical bottles carry a veneer of safety and legitimacy that misleads users, particularly adolescents, about the dangers involved.
Regulatory Challenges and Expert Views
Public health experts argue that while enforcement is crucial, the Varanasi scandal points to systemic gaps in the pharmaceutical supply chain.
“The existence of dozens of shell companies operating for years without detection indicates a need for digitalized, real-time tracking of Schedule H1 drugs,” notes a policy analyst from the Indian Public Health Association. “We need a system where every batch is traceable from the manufacturer to the patient’s prescription, leaving no room for ‘ghost firms’ to siphon off millions of units.”
The current investigation, led by a dedicated Special Investigation Team (SIT), is now probing the potential involvement of other state-level actors and expanding its scope to over 30 districts where the network might have tendrils.
Implications for Consumers
For the general public, this scandal serves as a stark reminder of the importance of purchasing medications from licensed, reputable pharmacies. The proliferation of diverted drugs also raises concerns about storage conditions and authenticity. Illegally trafficked medicines often bypass cold-chain requirements or could be counterfeit, posing additional health risks beyond addiction.
Authorities have urged citizens to report any suspicious bulk sales of cough syrups and to remain vigilant about the misuse of prescription medications within their communities.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Primary Story Source: Medical Dialogues. (2025, November 29). “12 more pharma firms booked in Varanasi cough syrup scandal.”
